BURTON ALEXANDER, MD
Specialist · NORFOLK, VA
Individual Active NPI 1841293966
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,528 | 275,010 | $16,293,346 | $3,824,912 | $3,065,691 |
| 2023 | 1,488 | 248,510 | $13,779,700 | $3,207,440 | $2,565,403 |
| 2022 | 1,645 | 386,239 | $19,610,095 | $5,057,539 | $4,046,076 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 118,735 | $3 | $2 |
| J9025 | Injection, azacitidine, 1 mg | 15,500 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 14,760 | $49 | $39 |
| J1453 | Injection, fosaprepitant, 1 mg | 4,050 | $0 | $0 |
| J9271 | Injection, pembrolizumab, 1 mg | 3,600 | $56 | $44 |
| J9041 | Injection, bortezomib, 0.1 mg | 2,940 | $2 | $1 |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,923 | $8 | $8 |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | 2,731 | $21 | $17 |
| J0897 | Injection, denosumab, 1 mg | 2,400 | $25 | $20 |
| J1750 | Injection, iron dextran, 50 mg | 2,323 | $17 | $13 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,170 | $20 | $16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,093 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Specialist | 174400000X | ✓ | 0101055171 | VA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Specialist providers in Virginia
- NPI 1619018637
- NPI 1356207104
- NPI 1861686404
- NPI 1649228461
- NPI 1982796090
- NPI 1255515300
- NPI 1942258082
- NPI 1417026907
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.